Clinical Trials Logo
  1. Home
  2. Exercise Induced Asthma
  3. NCT00861185

Study to Assess Safety and Efficacy of Oral Senicapoc Administration on Exercise-induced Asthma

Exercise Induced Asthma Clinical Trial

Official title:
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Assess the Safety and Efficacy of Four Weeks of Oral Senicapoc Administration on Exercise-Induced Asthma

Clinical Trial Summary

The purpose of this study is to determine whether 4 weeks of dosing with senicapoc alleviates exercise induced asthma symptoms.

Clinical Trial Description

Based on the unmet medical need for new agents in the treatment of asthma and the role of KCa3.1 in the function of several different cell types involved in the inflammatory response, and the effects seen in an animal model of allergic asthma, it is reasonable to explore the utility of senicapoc, a KCa3.1 blocker, as a novel treatment of asthma. This study will test the ability of senicapoc to alleviate bronchospasm induced by an exercise challenge in subjects with asthma. Exercise challenge studies have been conducted for many currently approved asthma medications. Exercise challenge studies provide a controlled environment and test conditions to investigate the potential usefulness of novel study drugs for the treatment of asthma. This study will be the first to test the ability of senicapoc to reduce airway bronchospasm after exercise challenge, which is one clinically important manifestation of asthma seen in patients. In summary, with a demonstrated safety profile across a wide range of doses in humans and efficacy in an animal model of allergic bronchospasm and hyper-responsiveness, the initiation of exploratory studies of senicapoc for treatment of asthma is justified. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00861185
Study type Interventional
Source Icagen
Contact
Status Completed
Phase Phase 2
Start date March 2009
Completion date September 2009
View Details
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT05162703 - Evaluation of Exercise Induced Bronchoconstriction Using a Novel Automated Digital Clinical Decision System N/A
Completed NCT00989833 - Comparing Symbicort® As-Needed or Bricanyl As-Needed or Pulmicort® Once Daily + Bricanyl As-Needed in Asthma Patients Phase 2
Recruiting NCT03524053 - Mediator Release During Exercise-induced Bronchoconstriction N/A
Completed NCT03550456 - Diagnostics and Quality of Life With EIA and EILO
Completed NCT05703334 - Kt and Myofascial Release in Exc Asthma N/A
Recruiting NCT05105529 - Adaptation to Ozone in Individuals With Asthma/Exercise-induced Bronchoconstriction N/A
Terminated NCT01070888 - Trial on the Effect of Budesonide/Formoterol and Inhaled Budesonide Alone on Exercise-Induced Asthma Phase 4
Recruiting NCT06336681 - Inspiratory Muscle Training on The Severity of Exercise-Induced Bronchoconstriction and Time-Trial Performance (IMT_EIB) Phase 2
Completed NCT01942096 - Study of Airway Inflammation in Relation to Exercise in Elite Athletes
Completed NCT00127166 - Two Investigational Drugs in the Prevention of Airway Constriction Brought on by Exercise in Participants With Asthma (0476-911) Phase 3
Recruiting NCT05174689 - Epigenetic Regulation of Exercise Induced Asthma N/A
Completed NCT01097954 - A Prospective Study Measuring Exhaled Nitric Oxide in Exercise-Induced Asthma